StockWatch
·
ANLON HEALTHCARE LTD · QQ2 FY-2027 · THE CALL

Strong revenue growth masks margin miss; execution risk elevated

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsAHCLAnlon Healthcare Ltd06 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

Revenue guidance on track (H1 ₹193 Cr vs. target ₹380-400 Cr annual). Margin guidance being missed by ~150 bps (23.9% actual vs. 25-30%).

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong revenue growth (102% YoY) and FY27 guidance tracking well (H1 ₹193 Cr toward ₹380-400 Cr target), but delivered Q2 margin of 23.9% fell short of 25-30% guidance due to raw material pricing and geopolitical pressure. FY28 growth target of ₹650-700 Cr is backed by concrete 1,200 MT expansion, but multiple new revenue streams (CDMO delayed to Q4, Medicos to Q3) remain unproven.

₹105.6 Cr

Revenue · +102.3% YoY

₹17.2 Cr

Reported PAT · +84.4% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Revenue growth 102.3% YoY, ₹105.61 Cr vs ₹52.2 Cr

MET

Delivered ₹105.6 Cr vs prior ₹52.2 Cr = 102.3% growth

PAT growth 84.4% YoY, ₹17.18 Cr vs ₹9.32 Cr

MET

Delivered ₹17.2 Cr vs prior ₹9.32 Cr = 84.4% growth

EBITDA margin recovery to 25%-30% range by Q3-Q4

OVERSTATED

Q2 actual margin 23.9% (EBITDA ₹25.24 Cr). Management acknowledges miss, blames raw material pricing pressure and geopolitical situation.

FY27 guidance ₹380-400 Cr on track

MET

H1 revenue ₹193.17 Cr (vs ₹85.5 Cr prior). At run-rate, tracking toward ₹380 Cr minimum.

Consolidated capacity 1,900-2,000 MT vs 400 MT prior

MET

Management states 1,900-2,000 MT consolidated (Anlon stand-alone at 85-86% utilization, consolidated at 65-67%).

Earnings quality

What changed since the last call

Deltas vs. the prior call

Margin guidance maintained but at risk

Downgrade

Prior call (Q1): 'stabilizing margin 25%-30%'. Q2 actual: 23.9%. Management says 'temporary' due to geopolitics, aiming for 25%-27% by year-end, but near-term pressure evident.

CDMO timeline pushed back

Downgrade

Management said 'expecting first revenue Q3 FY27'; now confirmed delayed to Q4. Molecule 1 validation complete but commercialization depends on customer ramp-up (not counted in FY28 projections).

Capital raise delayed

Downgrade

₹65-70 Cr equity raise for capex received approval in November. Funding needed for ₹130 Cr capex (₹70 Cr debt-funded). Timing risk could impact expansion pace.

FY28 guidance upgraded to ₹650-700 Cr

Upgrade

New forward guidance on Q2 call. Prior guidance was FY27 ₹350-400 Cr. FY28 adds 1,200 MT capacity by Q1, implies 67-80% growth.

The Q&A

Analysts pressed hard on margin miss (Vaibhav Mishra: 'can we expect margins above 24%?'), CDMO timeline (Rounak Baipai: 'when will first molecule commercialize?'), and acquisition impact (Bhavesh Patel: 'PAT margin decreasing, when steady-state?'). Management held up reasonably well, providing specific timelines (Q1 FY28 for expansion, Q4 for CDMO first revenue) and blaming external factors (raw material pricing) rather than operational issues. Some hedging on CDMO value-add ('too early to commit') and dividend ('will see cash flow first'). Overall, transparent but defensive tone.

The exchanges that mattered

FY27-FY28 revenue guidance — Nishita, Sapphire Capital

Answered

FY27 ₹380-400 Cr, almost in line with prior target. On track. FY28 ₹650-700 Cr (excluding CDMO).

Margin sustainability — Vaibhav Mishra, Finvestors Research

Partial

Situation improved from Q1. Achieved 23.9% in Q2. Hoping for 25%-26% by year-end as price revisions take effect. 23%-24% floor from raw material pressure; hope to reach 25%-27% sustainable.

Capacity expansion timeline — Vaibhav Mishra, Finvestors Research

Answered

Construction started. Finish first floor by end-November. Full commissioning by Q1 FY28. Possible 1-2 month delay if regulatory hurdles arise.

CDMO revenue timeline — Vaibhav Mishra, Finvestors Research

Answered

Delayed 1-2 months past Q3. Expected end-Q3 or early-Q4. Depends on customer ramp-up; not yet included in FY28 revenue projections.

Margin profile by segment — Rounak Baipai, Wealthtime Advisory

Answered

API ~35% gross EBITDA margin. Intermediate ~35%. Consolidated 65-67% utilization; Anlon stand-alone 85-86%.

CDMO commercialization and value-add — Rounak Baipai, Wealthtime Advisory

Partial

Molecule 1 commercial supply delayed to Q3-Q4. Molecules 2-3 validation by Q1 FY28. Too early to commit value to FY28 guidance. 1-3 years to market acceptability. Right now, focused on existing business.

Acquisition integration and EBITDA margin — Bhavesh Patel, Patel Investments

Partial

Apiqo is lower margin (20%-23% EBITDA) vs. pharma. Acquisition just 6, 8 months old. By FY27 you'll see improvement in ROE. FY28 profitability will improve from CDMO and new products. Sustainability: 25%-27% EBITDA, 11%-14% PAT (or 11%-13% consolidated impact).

DMF filing progress — Prateek Srivastava, Nivesh Vista

Answered

7 DMF planned in FY27. 3 almost done by Dec, another 2-3 by Q4. Ketoprofen US filing on hold pending customer (FDA trigger not yet started). ~6 DMF filed definitely by FY27, maybe 1-2 delayed.

Capital raise and debt — Deepak Chokhani, Raid Capital

Answered

₹65-70 Cr planned for capex and acquisitions. Approval received in November. Allotment and call within next 8-10 days. Total capex ₹130 Cr (₹70 Cr debt-funded).

Dividend and cash flow outlook — Bhavesh Patel, Patel Investments

Partial

Early to commit on dividend. Management will see cash flow first. H1 FY27 operating cash flow ₹7.94 Cr vs ₹79.44 Cr prior year (WC improved). Aiming for cash flow positive by end-FY27.

Medical device (Anlon Medicos) ramp and revenue — Priyansh Miri, NGP Family Office

Partial

Revenue starts Q3 FY27 (not material). FY28 ₹650-700 Cr base guidance excludes medical devices. Ointment topical gel expected Q1 FY28 DCGI approval; full pan-India launch. Revenue potential ₹70-80 Cr surgical devices business, ₹70-80 Cr ointment at peak.

Loxoprofen (Anlon Medicos) expansion — Priyansh Miri, NGP Family Office

Answered

Loxoprofen topical gel: CDSCO and DCGI approval expected FY28 (earliest Q1 FY28). Pan-India marketing. Existing tablet/capsule ₹80-90 Cr; ointment 2x-3x higher. Not included in FY28 ₹650-700 Cr guidance yet.

China Plus One strategy and moat — Priyansh Miri, NGP Family Office

Answered

No China dependency in our Ketoprofen, Desketoprofen, Loxoprofen portfolio. We're replacing Chinese manufacturers globally. Cost at par or 10%+ cheaper than China. Registration is moat, not price.

Guidance

Forward guidance and management's confidence

FY27 ₹380-400 Cr (reiterated)

High

H1 delivered ₹193.17 Cr; tracking well. Prior guidance from Q1 call maintained.

FY28 ₹650-700 Cr (new)

Medium

Base business guided; excludes CDMO first revenue and medical device ramp (expected Q3 start). Backed by 1,200 MT expansion by Q1 FY28.

EBITDA 25%-30% (maintained from Q1 call)

Low

Q2 actual 23.9%. Management targets 25%-27% recovery by year-end FY27; cites raw material normalization.

PAT margin 13%-14% core; 11%-13% consolidated

Medium

Apiqo acquisition at lower margin (20%-23% EBITDA). Consolidation drag evident; improvement expected as mix shifts toward higher-margin new products.

₹130 Cr capex FY27-FY28 (₹70 Cr debt, ₹65-70 Cr equity)

Medium

Equity raise approval received November 2026. Debt funding to support Rajkot expansion (1,200 MT) and Apiqo capex.

Risks the call surfaced

Ranked by how much they should concern a holder

Margin compression

High

Q2 margin 23.9% vs. 25%-30% guidance. Raw material (crude, petrochemical solvents) pricing post-geopolitical spike. Apiqo at 20%-23% margin (lower than Anlon core).

New product timing risk

High

CDMO first molecule delayed to Q4 (from Q3 guidance). Anlon Medicos surgical implants to start Q3 but minimal FY27 revenue. Loxoprofen ointment DCGI approval awaited (Q1 FY28 expected).

Integration execution risk

Medium

Apiqo (43.7% of H1 revenue) and Biozotic (11.7%) acquired early FY27; lower margin profile (20%-23% EBITDA vs. core 25%-27%). Consolidation drag evident in PAT margin.

Regulatory approval risk

Medium

7 DMF filings planned in FY27 (3 done by Q2, 6 by year-end targeted). Ketoprofen US filing on hold pending customer FDA trigger. Loxoprofen ointment DCGI approval expected Q1 FY28 but on hold for complexity and stability data.

Capacity expansion execution

Medium

Construction underway; finish first floor by end-November. Full commissioning targeted Q1 FY28 but at risk from regulatory/statutory approvals (mentioned 1-2 month possible delay).

Working capital cycle

Low

Receivables annualized 123 days (improved but still elevated). Payables 40 days. Management targeting 170-180 day optimal working capital cycle. Current position strains cash availability.

Management

Score 7/10. Clear and detailed on financial metrics and timelines. Transparent on margin miss (blames external factors, not opex). Candid on regulatory delays and project timelines. Some hedging on CDMO value-add and dividend. Revenue track record strong (102% YoY growth, H1 ₹193 Cr on guidance track). Margin guidance missed (23.9% vs. 25%-30%); management acknowledges and explains but recovery credibility tested. Acquisitions integrated (6-8 months old) but still drag on profitability.

What to watch next
  • 1 · Q3 FY27 (Nov-Dec 2026)

    Anlon Medicos revenue first contribution from surgical implants; DMF filings 3-4 more planned

  • 2 · Q4 FY27 (Jan-Mar 2027)

    CDMO first molecule commercial supply to start; Loxoprofen topical DCGI approval expected

  • 3 · Q1 FY28 (Apr-Jun 2027)

    Rajkot capacity expansion (1,200 MT, 8 new clean lines) commissioned; Anlon Biologies first revenue

FY28 growth target of ₹650-700 Cr is backed by concrete 1,200 MT expansion, but multiple new revenue streams (CDMO delayed to Q4, Medicos to Q3) remain unproven.

Informational and educational content only. Not investment advice.